作者: Supriya D. Mahajan , Wing-Cheung Law , Ravikumar Aalinkeel , Jessica Reynolds , Bindukumar B. Nair
DOI: 10.1016/B978-0-12-391858-1.00003-4
关键词: Controlled release 、 Pharmacology 、 In patient 、 Antiretroviral drug 、 Amprenavir 、 Antiretroviral therapy 、 Medicine 、 Quantum rods 、 Human immunodeficiency virus (HIV) 、 Blood–brain barrier
摘要: Abstract Nanotechnology offers a new platform for therapeutic delivery of antiretrovirals to the central nervous system (CNS) where human immunodeficiency virus (HIV-1) is sequestered in patients with HIV-1-associated neurological disorders (HAND). HAND spectrum neurocognitive that continue persist HIV-1-infected spite successful highly active antiretroviral therapy (HAART). Nanoformulated drugs offer multifunctionality, is, ability package multiple diagnostic and agents within same nanocomposite, along added provisions site-directed delivery, across blood–brain barrier (BBB), controlled release therapeutics. We have stably incorporated drug, Amprenavir, transferrin (Tf)-conjugated quantum dot (QD), evaluated transversing this Tf-QD-Amprenavir nanoplex an vitro BBB model analyzed its antiviral efficacy monocytes. describe methods synthesis approaches evaluate both capability efficacy.